188:@0.085057:0.957873:0.109689:0.957873:0.109689:0.938882:0.085057:0.938882:0.007450:0.008591:0.008591
ADDENDUM:@0.117647:0.067543:0.201421:0.067543:0.201421:0.045457:0.117647:0.045457:0.009679:0.010295:0.010295:0.008697:0.010706:0.010295:0.010226:0.013582
gins of ovarian cancers: pathogenesis and prevention strategies. Nat. Rev. Cancer 17, 65–74 :@0.155000:0.119718:0.856768:0.119718:0.856768:0.101197:0.155000:0.101197:0.008965:0.005105:0.010563:0.006973:0.004275:0.009857:0.005644:0.004275:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.004275:0.008280:0.008259:0.010542:0.008176:0.008218:0.006931:0.006973:0.004088:0.004275:0.010334:0.008010:0.006018:0.010272:0.010044:0.008778:0.008218:0.010542:0.008218:0.006910:0.005105:0.006973:0.004275:0.008259:0.010542:0.010355:0.004275:0.010065:0.006765:0.008487:0.008757:0.008218:0.010355:0.005852:0.005043:0.009857:0.010687:0.004275:0.006827:0.005852:0.007180:0.008010:0.005644:0.008218:0.008965:0.005043:0.008218:0.006973:0.004088:0.004275:0.014132:0.008010:0.005852:0.004088:0.004275:0.012451:0.008487:0.007367:0.004088:0.004275:0.013611:0.008259:0.010544:0.008176:0.008218:0.007097:0.004264:0.009483:0.009483:0.004088:0.004275:0.009483:0.009483:0.010729:0.009483:0.009483:0.003735
(2017).:@0.155000:0.140297:0.209639:0.140297:0.209639:0.121776:0.155000:0.121776:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
75.  Ng, A. & Barker, N. Ovary and fimbrial stem cells: biology, niche and cancer origins. Nat. :@0.117647:0.160875:0.856573:0.160875:0.856573:0.142355:0.117647:0.142355:0.009483:0.009483:0.004088:0.003735:0.010563:0.014049:0.008799:0.004088:0.005333:0.013572:0.004088:0.005333:0.014298:0.005333:0.011704:0.008259:0.006910:0.009338:0.008218:0.005686:0.004088:0.005333:0.014754:0.004088:0.005333:0.015356:0.008944:0.008259:0.007637:0.008840:0.005333:0.008261:0.010542:0.010355:0.005333:0.005167:0.005167:0.015813:0.009836:0.007097:0.005271:0.008550:0.004773:0.005333:0.006827:0.005644:0.008218:0.016041:0.005333:0.008176:0.008135:0.004897:0.004773:0.006973:0.004088:0.005333:0.009836:0.005043:0.009940:0.004711:0.010044:0.009587:0.007263:0.004088:0.005333:0.010687:0.005041:0.007971:0.010272:0.008218:0.005333:0.008259:0.010542:0.010355:0.005333:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.005333:0.009857:0.007097:0.005105:0.008965:0.005105:0.010563:0.006973:0.004088:0.005333:0.014132:0.008010:0.005852:0.004088:0.003735
Rev. Mol. Cell Biol. 16, 625–638 (2015).:@0.155000:0.181454:0.457307:0.181454:0.457307:0.162933:0.155000:0.162933:0.012451:0.008487:0.007367:0.004088:0.003735:0.017245:0.009940:0.004524:0.004088:0.003735:0.013632:0.008135:0.004897:0.004773:0.003735:0.011351:0.005043:0.009940:0.004524:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
76.  Torre, L. A. :@0.117647:0.202033:0.247635:0.202033:0.247635:0.183512:0.117647:0.183512:0.009483:0.009483:0.004088:0.003735:0.010563:0.009878:0.009857:0.007097:0.006765:0.007948:0.004088:0.005478:0.010563:0.004088:0.005478:0.013572:0.004088:0.003735
et al.:@0.249392:0.202033:0.286310:0.202033:0.286310:0.183321:0.249392:0.183321:0.007346:0.005727:0.005603:0.009048:0.004607:0.004586
 Ovarian cancer statistics, 2018. CA: A Cancer Journal for Clinicians 68, :@0.286311:0.202033:0.856626:0.202033:0.856626:0.183512:0.286311:0.183512:0.005478:0.015356:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.005478:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.005478:0.006827:0.005956:0.008010:0.005852:0.005105:0.006827:0.005852:0.005043:0.008176:0.006973:0.004088:0.005478:0.009483:0.009483:0.009483:0.009483:0.004088:0.005478:0.013343:0.013572:0.004088:0.005478:0.013572:0.005478:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.005478:0.005665:0.009836:0.010376:0.007097:0.010625:0.008550:0.004773:0.005478:0.005478:0.009857:0.007097:0.005478:0.013406:0.004773:0.005105:0.010687:0.005041:0.008176:0.005271:0.008259:0.010563:0.006973:0.005478:0.009483:0.009483:0.004088:0.003735
284–296 (2018).:@0.155000:0.222612:0.281004:0.222612:0.281004:0.204091:0.155000:0.204091:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
77.  Network, T. C. G. A. R. & The Cancer Genome Atlas Research Network. Integrated genomic :@0.117647:0.243190:0.856760:0.243190:0.856760:0.224669:0.117647:0.224669:0.009483:0.009483:0.004088:0.003735:0.010563:0.014111:0.008301:0.005852:0.013198:0.009857:0.006910:0.009566:0.004088:0.003549:0.009961:0.004088:0.003549:0.013343:0.004088:0.003538:0.014256:0.004088:0.003549:0.013572:0.004088:0.003549:0.012451:0.004088:0.003549:0.014298:0.003538:0.010428:0.010285:0.008218:0.003538:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003549:0.014381:0.008218:0.010542:0.009857:0.015896:0.008218:0.003549:0.012721:0.006018:0.004939:0.008446:0.006973:0.003549:0.012451:0.008218:0.007159:0.008444:0.008259:0.006765:0.007971:0.010417:0.003538:0.014113:0.008299:0.005852:0.013198:0.009857:0.006910:0.009566:0.004088:0.003549:0.006267:0.010355:0.005647:0.008218:0.008965:0.007178:0.008010:0.005644:0.008280:0.010355:0.003549:0.008778:0.008218:0.010542:0.009857:0.016041:0.005043:0.008176:0.003735
analyses of ovarian carcinoma. Nature 474, 609–615 (2011).:@0.155000:0.263769:0.611783:0.263769:0.611783:0.245248:0.155000:0.245248:0.008259:0.010625:0.008550:0.004711:0.008840:0.007159:0.008218:0.006973:0.003735:0.009857:0.005644:0.003735:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.003735:0.008278:0.008261:0.006765:0.008176:0.005105:0.010542:0.009857:0.015979:0.008446:0.004088:0.003735:0.014130:0.008010:0.005603:0.010376:0.006765:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
78.  Patch, A.-M. :@0.117647:0.284348:0.254919:0.284348:0.254919:0.265827:0.117647:0.265827:0.009483:0.009483:0.004088:0.003735:0.010563:0.010376:0.008010:0.005644:0.007969:0.010417:0.004088:0.003258:0.013572:0.004088:0.006848:0.017826:0.004088:0.003735
et al.:@0.254439:0.284348:0.289082:0.284348:0.289082:0.265636:0.254439:0.265636:0.007346:0.005727:0.003329:0.009048:0.004607:0.004586
 Whole-genome characterization of chemoresistant ovarian cancer. Nature :@0.289082:0.284348:0.856681:0.284348:0.856681:0.265827:0.289082:0.265827:0.003258:0.018822:0.010272:0.009940:0.004711:0.008218:0.006848:0.008778:0.008218:0.010542:0.009857:0.015896:0.008218:0.003258:0.007969:0.010355:0.008259:0.007180:0.008446:0.008278:0.005647:0.008218:0.007097:0.005105:0.008031:0.008008:0.005852:0.005043:0.009857:0.010687:0.003258:0.009857:0.005644:0.003258:0.007971:0.010270:0.008218:0.015898:0.009857:0.006765:0.008218:0.006910:0.005105:0.006827:0.005956:0.008259:0.010355:0.005852:0.003258:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.003258:0.008280:0.008259:0.010542:0.008176:0.008218:0.005686:0.004088:0.003258:0.014132:0.008010:0.005603:0.010376:0.006765:0.008218:0.003735
521, 489–494 (2015).:@0.155000:0.304926:0.317278:0.304926:0.317278:0.286406:0.155000:0.286406:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
79.  Prat, J., Ribé, A. & Gallardo, A. Hereditary ovarian cancer. Human Pathology 36, 861–870 :@0.117647:0.325505:0.856726:0.325505:0.856726:0.306984:0.117647:0.306984:0.009483:0.009483:0.004088:0.003735:0.010563:0.010832:0.007180:0.008010:0.005852:0.004088:0.004949:0.005107:0.004088:0.004088:0.004949:0.012264:0.005043:0.010231:0.007948:0.004088:0.004949:0.013572:0.004088:0.004960:0.014298:0.004949:0.014360:0.008550:0.004897:0.004939:0.008259:0.006765:0.010293:0.009338:0.004088:0.004960:0.013572:0.004088:0.004949:0.014734:0.008218:0.006765:0.008280:0.010355:0.004794:0.005956:0.008259:0.007635:0.008840:0.004960:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.004960:0.008278:0.008261:0.010542:0.008176:0.008218:0.005686:0.004088:0.004949:0.014402:0.010376:0.015979:0.008259:0.010687:0.004960:0.010376:0.008010:0.006018:0.010272:0.009940:0.004711:0.010044:0.009587:0.008840:0.004960:0.009483:0.009483:0.004088:0.004949:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735
(2005).:@0.155000:0.346084:0.209639:0.346084:0.209639:0.327563:0.155000:0.327563:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
80.  Walsh, T. :@0.117647:0.366663:0.229903:0.366663:0.229903:0.348142:0.117647:0.348142:0.009483:0.009483:0.004088:0.003735:0.010563:0.017079:0.008550:0.004773:0.006869:0.010417:0.004088:0.005344:0.009961:0.004088:0.003735
et al.:@0.231513:0.366663:0.268282:0.366663:0.268282:0.347951:0.231513:0.347951:0.007346:0.005727:0.005458:0.009046:0.004607:0.004586
 Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal :@0.268289:0.366663:0.856701:0.366663:0.856701:0.348142:0.268289:0.348142:0.005344:0.016954:0.010065:0.005956:0.008010:0.005852:0.005043:0.009857:0.010563:0.006973:0.005354:0.005105:0.010687:0.005344:0.009483:0.009483:0.005344:0.008778:0.008218:0.010542:0.008218:0.006973:0.005354:0.005478:0.009857:0.007097:0.005344:0.005105:0.010791:0.010272:0.008218:0.007097:0.004794:0.005644:0.008278:0.010355:0.005354:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.004088:0.005344:0.005644:0.008550:0.004897:0.004711:0.009836:0.010065:0.005271:0.008259:0.010687:0.005344:0.005603:0.010314:0.010231:0.007948:0.004088:0.005344:0.008261:0.010542:0.010355:0.005344:0.010459:0.008218:0.007097:0.004794:0.005644:0.009857:0.010542:0.008446:0.008550:0.004773:0.003735
carcinoma identified by massively parallel sequencing. Proc. Natl. Acad. Sci. U. S. A. 108, :@0.155000:0.387241:0.856733:0.387241:0.856733:0.368720:0.155000:0.368720:0.008280:0.008259:0.006765:0.008176:0.005105:0.010542:0.009857:0.015979:0.008446:0.005769:0.005043:0.010293:0.008218:0.010355:0.005852:0.005105:0.005167:0.005105:0.008280:0.010355:0.005769:0.009857:0.008840:0.005769:0.015979:0.008446:0.006848:0.006910:0.005043:0.008757:0.008135:0.004711:0.008840:0.005769:0.010334:0.008259:0.007180:0.008550:0.004897:0.004711:0.008135:0.004773:0.005769:0.007159:0.008278:0.009733:0.010316:0.008218:0.010542:0.008176:0.005105:0.010417:0.008797:0.004088:0.005769:0.010832:0.006765:0.010251:0.008176:0.004088:0.005769:0.014132:0.008010:0.006018:0.004524:0.004088:0.005769:0.013032:0.008280:0.008446:0.010106:0.004088:0.005769:0.009627:0.008176:0.004856:0.004088:0.005769:0.012638:0.004088:0.005769:0.009193:0.004088:0.005769:0.013572:0.004088:0.005769:0.009483:0.009483:0.009483:0.004088:0.003735
18032–18037 (2011).:@0.155000:0.407820:0.318938:0.407820:0.318938:0.389299:0.155000:0.389299:0.009483:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
81.  Toss, A. :@0.117647:0.428399:0.219712:0.428399:0.219712:0.409878:0.117647:0.409878:0.009483:0.009483:0.004088:0.003735:0.010563:0.009878:0.009961:0.006848:0.006973:0.004088:0.005570:0.013572:0.004088:0.003735
et al.:@0.221548:0.428399:0.258548:0.428399:0.258548:0.409687:0.221548:0.409687:0.007346:0.005727:0.005686:0.009048:0.004607:0.004586
 Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res. Int. :@0.258556:0.428399:0.856676:0.428399:0.856676:0.409878:0.258556:0.409878:0.005572:0.014734:0.008218:0.006765:0.008278:0.010355:0.004794:0.005956:0.008259:0.007637:0.008840:0.005570:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.005572:0.008280:0.008259:0.010542:0.008176:0.008218:0.007388:0.004088:0.005570:0.010542:0.009836:0.005852:0.005572:0.009857:0.010791:0.004711:0.008840:0.005570:0.011330:0.012098:0.013343:0.013572:0.005572:0.009483:0.005570:0.008259:0.010542:0.010355:0.005572:0.009483:0.005570:0.008778:0.008218:0.010542:0.008218:0.006973:0.004088:0.005572:0.011351:0.005043:0.009857:0.015896:0.008280:0.010355:0.005570:0.012451:0.008218:0.006973:0.004088:0.005570:0.006267:0.010357:0.005852:0.004088:0.003735
2015, 341723 (2015).:@0.155000:0.448977:0.316032:0.448977:0.316032:0.430456:0.155000:0.430456:0.009483:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
82.  Wang, Y. K. :@0.117647:0.469556:0.245934:0.469556:0.245934:0.451035:0.117647:0.451035:0.009483:0.009483:0.004088:0.003735:0.010563:0.017079:0.008259:0.010417:0.008799:0.004088:0.003798:0.009566:0.004088:0.003798:0.013219:0.004088:0.003735
et al.:@0.245978:0.469556:0.281172:0.469556:0.281172:0.450844:0.245978:0.450844:0.007346:0.005727:0.003881:0.009048:0.004607:0.004586
 Genomic consequences of aberrant DNA repair mechanisms stratify ovar-:@0.281166:0.469556:0.852941:0.469556:0.852941:0.451035:0.281166:0.451035:0.003798:0.014381:0.008218:0.010542:0.009857:0.016041:0.005043:0.008176:0.003798:0.008176:0.009857:0.010563:0.007159:0.008280:0.009733:0.010314:0.008218:0.010542:0.008176:0.008218:0.006973:0.003798:0.009857:0.005644:0.003798:0.008280:0.010231:0.008218:0.007097:0.007178:0.008259:0.010357:0.005852:0.003798:0.014339:0.014007:0.013572:0.003798:0.006765:0.008301:0.010334:0.008259:0.005105:0.007097:0.003798:0.015896:0.008280:0.007969:0.010355:0.008259:0.010687:0.005105:0.006910:0.015916:0.006973:0.003798:0.006827:0.005852:0.007180:0.008010:0.005852:0.005105:0.005914:0.008840:0.003798:0.009878:0.008944:0.008259:0.006521:0.006848
ian cancer histotypes. Nat. Genet. 49, 856–865 (2017).:@0.155000:0.490135:0.566980:0.490135:0.566980:0.471614:0.155000:0.471614:0.005271:0.008259:0.010687:0.003735:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.010417:0.005105:0.006827:0.005644:0.009836:0.005852:0.008840:0.010457:0.008218:0.006973:0.004088:0.003735:0.014132:0.008010:0.005852:0.004088:0.003735:0.014381:0.008218:0.010542:0.008301:0.005852:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
83.  Farmer, H. :@0.117647:0.510713:0.240237:0.510713:0.240237:0.492193:0.117647:0.492193:0.009483:0.009483:0.004088:0.003735:0.010563:0.009753:0.008259:0.007097:0.015896:0.008218:0.005686:0.004088:0.003102:0.015315:0.004088:0.003735
et al.:@0.239604:0.510713:0.274093:0.510713:0.274093:0.492001:0.239604:0.492001:0.007346:0.005727:0.003175:0.009048:0.004607:0.004586
 Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strat-:@0.274088:0.510713:0.852941:0.510713:0.852941:0.492193:0.274088:0.492193:0.003102:0.009919:0.008259:0.006931:0.008778:0.008301:0.005852:0.005105:0.010417:0.008965:0.003102:0.006018:0.010272:0.008218:0.003102:0.014339:0.014007:0.013572:0.003102:0.006765:0.008301:0.010334:0.008259:0.005105:0.007097:0.003102:0.010293:0.008218:0.005476:0.008280:0.008280:0.005852:0.003102:0.005105:0.010687:0.003102:0.011330:0.012098:0.013343:0.013572:0.003102:0.015709:0.010065:0.005956:0.008259:0.010355:0.005852:0.003102:0.008176:0.008135:0.004897:0.004773:0.006973:0.003102:0.008446:0.006973:0.003100:0.008446:0.003102:0.006018:0.010274:0.008218:0.007178:0.008012:0.010457:0.008301:0.010065:0.005852:0.005043:0.008176:0.003102:0.006827:0.005852:0.007180:0.008010:0.005853:0.006848
egy. Nature 434, 917–921 (2005).:@0.155000:0.531292:0.407008:0.531292:0.407008:0.512771:0.155000:0.512771:0.008218:0.009587:0.007263:0.004088:0.003735:0.014132:0.008010:0.005603:0.010376:0.006765:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
84.  Pommier, Y., O’Connor, M. J. & de Bono, J. Laying a trap to kill cancer cells: PARP inhibitors :@0.117647:0.551871:0.856714:0.551871:0.856714:0.533350:0.117647:0.533350:0.009483:0.009483:0.004088:0.003735:0.010563:0.010148:0.009857:0.016041:0.016041:0.005043:0.008218:0.005686:0.004088:0.003777:0.009566:0.004088:0.004088:0.003777:0.013717:0.002511:0.013634:0.009855:0.010687:0.010544:0.009857:0.005686:0.004088:0.003777:0.017826:0.004088:0.003777:0.005103:0.004088:0.003777:0.014298:0.003777:0.010293:0.008218:0.003777:0.011889:0.009857:0.010544:0.009338:0.004088:0.003777:0.005105:0.004088:0.003777:0.010895:0.008114:0.008840:0.005105:0.010417:0.008965:0.003777:0.008446:0.003777:0.005852:0.007180:0.008010:0.010251:0.003777:0.005644:0.010044:0.003777:0.009733:0.005229:0.004897:0.004773:0.003777:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.003777:0.008176:0.008135:0.004897:0.004773:0.006973:0.004088:0.003777:0.009317:0.013572:0.012160:0.011061:0.003777:0.005105:0.010791:0.010417:0.005043:0.009836:0.004794:0.005644:0.009857:0.006931:0.006973:0.003735
and their mechanisms of action. Sci. Transl. Med. 8, 362ps17 (2016).:@0.155000:0.572450:0.673247:0.572450:0.673247:0.553929:0.155000:0.553929:0.008259:0.010542:0.010355:0.003735:0.006018:0.010272:0.008218:0.005105:0.007097:0.003735:0.015896:0.008280:0.007969:0.010355:0.008259:0.010687:0.005105:0.006910:0.015916:0.006973:0.003735:0.009857:0.005644:0.003735:0.008446:0.008278:0.005852:0.005043:0.009857:0.010687:0.004088:0.003735:0.009629:0.008176:0.004856:0.004088:0.003735:0.010210:0.007180:0.008259:0.010563:0.006869:0.004524:0.004088:0.003735:0.017245:0.008280:0.010106:0.004088:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010166:0.006973:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
85.  Mateo, J. :@0.117647:0.593028:0.226562:0.593028:0.226562:0.574507:0.117647:0.574507:0.009483:0.009483:0.004088:0.003735:0.010563:0.017348:0.008010:0.005644:0.008280:0.009338:0.004088:0.005925:0.005105:0.004088:0.003735
et al.:@0.228754:0.593028:0.266127:0.593028:0.266127:0.574316:0.228754:0.574316:0.007346:0.005727:0.006059:0.009048:0.004607:0.004586
 A decade of clinical development of PARP inhibitors in perspective. Ann. :@0.266125:0.593028:0.856735:0.593028:0.856735:0.574507:0.266125:0.574507:0.005935:0.013572:0.005925:0.010293:0.008280:0.008280:0.008446:0.010293:0.008218:0.005935:0.009857:0.005644:0.005925:0.007971:0.004773:0.005105:0.010687:0.005041:0.008280:0.008550:0.004773:0.005935:0.010293:0.008487:0.008757:0.008135:0.004711:0.009836:0.010065:0.015896:0.008218:0.010355:0.005852:0.005925:0.009857:0.005644:0.005935:0.009317:0.013572:0.012160:0.011061:0.005935:0.005105:0.010789:0.010417:0.005043:0.009836:0.004794:0.005644:0.009857:0.006931:0.006973:0.005935:0.005105:0.010687:0.005925:0.010459:0.008218:0.006931:0.006827:0.010459:0.008280:0.008280:0.005852:0.005043:0.008757:0.007948:0.004088:0.005935:0.013572:0.010687:0.010687:0.004088:0.003735
Oncol. 30, 1437–1447 (2019).:@0.155000:0.613607:0.382583:0.613607:0.382583:0.595086:0.155000:0.595086:0.014817:0.010542:0.008176:0.009940:0.004524:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
86.  Hoogstraat, M. :@0.117647:0.634186:0.274405:0.634186:0.274405:0.615665:0.117647:0.615665:0.009483:0.009483:0.004088:0.003735:0.010563:0.014734:0.010251:0.010044:0.008840:0.006827:0.005852:0.007180:0.008529:0.008010:0.005852:0.004088:0.003549:0.017826:0.004088:0.003735
et al.:@0.274203:0.634186:0.309139:0.634186:0.309139:0.615474:0.274203:0.615474:0.007346:0.005727:0.003619:0.009050:0.004607:0.004586
 Genomic and transcriptomic plasticity in treatment-naive ovarian can-:@0.309137:0.634186:0.852941:0.634186:0.852941:0.615665:0.309137:0.615665:0.003549:0.014381:0.008218:0.010542:0.009857:0.016041:0.005043:0.008176:0.003549:0.008259:0.010542:0.010355:0.003549:0.005852:0.007180:0.008259:0.010563:0.007159:0.008176:0.007097:0.004792:0.010044:0.005644:0.009857:0.016041:0.005043:0.008176:0.003549:0.010148:0.004939:0.008446:0.006827:0.005852:0.005043:0.008176:0.004794:0.005852:0.008840:0.003549:0.005105:0.010687:0.003549:0.005852:0.006765:0.008446:0.008010:0.005852:0.015896:0.008218:0.010355:0.005852:0.006848:0.010625:0.008259:0.005043:0.008757:0.008218:0.003549:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.003549:0.008280:0.008259:0.010634:0.006848
cer. Genome Research 24, 200–211 (2014).:@0.155000:0.654764:0.481962:0.654764:0.481962:0.636244:0.155000:0.636244:0.008176:0.008218:0.005686:0.004088:0.003735:0.014381:0.008218:0.010542:0.009857:0.015896:0.008218:0.003735:0.012451:0.008218:0.007157:0.008446:0.008259:0.006765:0.007971:0.010417:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
87.  Caponigro, G. & Sellers, W. R. Advances in the preclinical testing of cancer therapeutic hy-:@0.117647:0.675343:0.852941:0.675343:0.852941:0.656822:0.117647:0.656822:0.009483:0.009483:0.004088:0.003735:0.010563:0.013613:0.008010:0.010459:0.009857:0.010687:0.005105:0.008965:0.006765:0.009336:0.004088:0.004503:0.014256:0.004088:0.004503:0.014298:0.004503:0.009629:0.008135:0.004897:0.004711:0.008218:0.006931:0.006973:0.004088:0.004503:0.015813:0.004088:0.004503:0.012449:0.004088:0.004503:0.013032:0.010293:0.008944:0.008259:0.010542:0.008176:0.008218:0.006973:0.004503:0.005105:0.010687:0.004503:0.006018:0.010272:0.008218:0.004503:0.010065:0.006765:0.008280:0.007969:0.004773:0.005105:0.010687:0.005043:0.008280:0.008550:0.004773:0.004493:0.005644:0.008218:0.006827:0.005852:0.005105:0.010417:0.008965:0.004503:0.009857:0.005644:0.004503:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.004503:0.006018:0.010272:0.008218:0.007180:0.008010:0.010459:0.008301:0.010065:0.005852:0.005043:0.008176:0.004503:0.010065:0.008732:0.006848
potheses. Nat. Rev. Drug Discov. 10, 179–187 (2011).:@0.155000:0.695922:0.559673:0.695922:0.559673:0.677401:0.155000:0.677401:0.010459:0.009836:0.006018:0.010272:0.008218:0.007159:0.008218:0.006973:0.004088:0.003735:0.014130:0.008010:0.005852:0.004088:0.003735:0.012451:0.008487:0.007367:0.004088:0.003735:0.014568:0.007242:0.010376:0.008965:0.003735:0.014568:0.005105:0.007157:0.008176:0.009878:0.007367:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
88.  Voskoglou-Nomikos, T., Pater, J. L. & Seymour, L. Clinical predictive value of the :@0.117647:0.716500:0.770553:0.716500:0.770553:0.697980:0.117647:0.697980:0.009483:0.009483:0.004088:0.003735:0.010563:0.011579:0.009961:0.006869:0.009338:0.010044:0.009027:0.004711:0.009836:0.010376:0.006848:0.014111:0.009857:0.016041:0.005229:0.009338:0.009961:0.006973:0.004088:0.003673:0.009961:0.004088:0.004088:0.003673:0.010374:0.008012:0.005644:0.008218:0.005686:0.004088:0.003673:0.005105:0.004088:0.003673:0.010563:0.004088:0.003673:0.014298:0.003673:0.009629:0.008487:0.008840:0.015896:0.009836:0.010376:0.005686:0.004088:0.003673:0.010563:0.004088:0.003673:0.013406:0.004773:0.005105:0.010687:0.005041:0.008280:0.008550:0.004773:0.003673:0.010065:0.006765:0.008280:0.010355:0.005043:0.008280:0.005852:0.005043:0.008757:0.008218:0.003673:0.008944:0.008550:0.004462:0.010314:0.008218:0.003673:0.009857:0.005644:0.003673:0.006018:0.010272:0.008218:0.003735
in vitro:@0.770460:0.716500:0.823294:0.716500:0.823294:0.697789:0.770460:0.697789:0.004628:0.010272:0.003756:0.008446:0.004731:0.005333:0.006641:0.009027
 cell :@0.823289:0.716500:0.856678:0.716500:0.856678:0.697980:0.823289:0.697980:0.003673:0.008176:0.008135:0.004897:0.004773:0.003735
line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 9, :@0.155000:0.737079:0.856699:0.737079:0.856699:0.718558:0.155000:0.718558:0.004773:0.005105:0.010542:0.007948:0.004088:0.004794:0.010087:0.010376:0.015979:0.008259:0.010687:0.004794:0.008985:0.008218:0.010542:0.010044:0.008965:0.007180:0.008259:0.005634:0.005634:0.004088:0.004794:0.008259:0.010544:0.010355:0.004794:0.015896:0.009836:0.010376:0.007159:0.008218:0.004794:0.008550:0.004897:0.004711:0.010044:0.008965:0.007180:0.008259:0.005634:0.005634:0.004794:0.010065:0.006765:0.008278:0.007969:0.004773:0.005105:0.010687:0.005043:0.008280:0.008550:0.004773:0.004794:0.008280:0.008259:0.010544:0.008176:0.008218:0.007097:0.004794:0.015896:0.010251:0.010293:0.008135:0.004773:0.006973:0.004088:0.004794:0.013406:0.004773:0.005105:0.010687:0.004088:0.004794:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.004794:0.012451:0.008218:0.006973:0.004088:0.004794:0.009483:0.004088:0.003735
4227–4239 (2003).:@0.155000:0.757658:0.299971:0.757658:0.299971:0.739137:0.155000:0.739137:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
89.  Pauli, C. :@0.117647:0.778237:0.221965:0.778237:0.221965:0.759716:0.117647:0.759716:0.009483:0.009483:0.004088:0.003735:0.010563:0.010376:0.008010:0.010500:0.004773:0.004856:0.004088:0.003196:0.013343:0.004088:0.003735
et al.:@0.221431:0.778237:0.256014:0.778237:0.256014:0.759525:0.221431:0.759525:0.007346:0.005727:0.003268:0.009048:0.004607:0.004586
 Personalized and Cancer Models to Guide Precision Medicine. Cancer Discov. :@0.256014:0.778237:0.856652:0.778237:0.856652:0.759716:0.256014:0.759716:0.003196:0.010145:0.008218:0.006931:0.007159:0.009857:0.010625:0.008550:0.004773:0.005105:0.008031:0.008280:0.010355:0.003196:0.008259:0.010544:0.010355:0.003196:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003196:0.017245:0.010251:0.010293:0.008135:0.004773:0.006973:0.003196:0.005647:0.010044:0.003196:0.013883:0.010376:0.005043:0.010293:0.008218:0.003196:0.010832:0.006767:0.008278:0.008176:0.005105:0.006910:0.005043:0.009857:0.010687:0.003196:0.017245:0.008280:0.010355:0.005043:0.008176:0.005105:0.010540:0.007950:0.004088:0.003196:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003196:0.014568:0.005105:0.007159:0.008176:0.009878:0.007367:0.004088:0.003735
7, 462–477 (2017).:@0.155000:0.798815:0.298311:0.798815:0.298311:0.780294:0.155000:0.780294:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
90.  Gey, G. O., Coffman, W. D. & Kubicek, M. T. Tissue culture studies of the proliferative capac-:@0.117647:0.819394:0.852941:0.819394:0.852941:0.800873:0.117647:0.800873:0.009483:0.009483:0.004088:0.003735:0.010563:0.014381:0.008487:0.007263:0.004088:0.003383:0.014256:0.004088:0.003383:0.013987:0.004088:0.004088:0.003383:0.013634:0.009857:0.005427:0.005613:0.015979:0.008259:0.010687:0.004088:0.003383:0.015813:0.004088:0.003383:0.013738:0.004088:0.003383:0.014298:0.003383:0.012409:0.010314:0.009836:0.005043:0.008176:0.008135:0.009566:0.004088:0.003383:0.017826:0.004088:0.003383:0.009961:0.004088:0.003383:0.011579:0.005105:0.006848:0.006827:0.010314:0.008218:0.003383:0.008280:0.010500:0.004462:0.005603:0.010376:0.006765:0.008218:0.003383:0.006827:0.005603:0.010314:0.010355:0.005043:0.008218:0.006973:0.003383:0.009857:0.005644:0.003383:0.006018:0.010272:0.008218:0.003383:0.010065:0.006765:0.009940:0.004773:0.005105:0.005478:0.008218:0.007180:0.008010:0.005852:0.005043:0.008757:0.008218:0.003383:0.008280:0.008010:0.010334:0.008446:0.008240:0.006848
ity of cervical carcinoma and normal epithelium. Cancer Res. 12, 264–265 (1952).:@0.155000:0.839973:0.778665:0.839973:0.778665:0.821452:0.155000:0.821452:0.004794:0.005852:0.008840:0.003735:0.009857:0.005644:0.003735:0.008176:0.008218:0.007635:0.008944:0.005043:0.008280:0.008550:0.004773:0.003735:0.008280:0.008259:0.006765:0.008176:0.005105:0.010542:0.009857:0.015979:0.008446:0.003735:0.008259:0.010542:0.010355:0.003735:0.010542:0.009857:0.007097:0.015979:0.008550:0.004773:0.003735:0.008301:0.010065:0.004794:0.006018:0.010272:0.008135:0.004773:0.004794:0.010376:0.016041:0.004088:0.003735:0.013611:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.012451:0.008218:0.006973:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
91.  Adey, A. :@0.117647:0.860551:0.222899:0.860551:0.222899:0.842031:0.117647:0.842031:0.009483:0.009483:0.004088:0.003735:0.010563:0.013032:0.010293:0.008487:0.007263:0.004088:0.003341:0.013572:0.004088:0.003735
et al.:@0.222522:0.860551:0.257260:0.860551:0.257260:0.841839:0.222522:0.841839:0.007346:0.005727:0.003424:0.009048:0.004607:0.004586
 The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer :@0.257260:0.860551:0.856588:0.860551:0.856588:0.842031:0.257260:0.842031:0.003341:0.010428:0.010282:0.008218:0.003341:0.010355:0.008010:0.010148:0.004711:0.009836:0.005852:0.008840:0.010457:0.008218:0.006848:0.006765:0.008218:0.007159:0.009940:0.004711:0.008757:0.008280:0.010355:0.003341:0.008778:0.008218:0.010544:0.009855:0.015898:0.008218:0.003341:0.008259:0.010542:0.010355:0.003341:0.008301:0.010065:0.005105:0.008778:0.008218:0.010542:0.009857:0.015896:0.008218:0.003341:0.009857:0.005644:0.003341:0.006018:0.010272:0.008218:0.003341:0.008259:0.010542:0.008301:0.010065:0.010148:0.004711:0.009857:0.005043:0.010355:0.003341:0.014732:0.008218:0.010895:0.008446:0.003341:0.008280:0.008259:0.010544:0.008176:0.008218:0.007097:0.003735
cell line. Nature 500, 207–211 (2013).:@0.155000:0.881130:0.440023:0.881130:0.440023:0.862609:0.155000:0.862609:0.008176:0.008135:0.004897:0.004773:0.003735:0.004773:0.005105:0.010542:0.007948:0.004088:0.003735:0.014132:0.008010:0.005603:0.010376:0.006765:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
92.  Scherer, W. F., Syverton, J. T. & Gey, G. O. Studies on the propagation :@0.117647:0.901709:0.677671:0.901709:0.677671:0.883188:0.117647:0.883188:0.009483:0.009483:0.004088:0.003735:0.010563:0.009629:0.007969:0.010272:0.008218:0.006765:0.008218:0.005686:0.004088:0.003611:0.015813:0.004088:0.003611:0.007906:0.004088:0.004088:0.003611:0.008923:0.009338:0.008757:0.008218:0.007242:0.005644:0.009857:0.010687:0.004088:0.003611:0.005105:0.004088:0.003611:0.009961:0.004088:0.003611:0.014298:0.003611:0.014381:0.008487:0.007263:0.004088:0.003611:0.014256:0.004088:0.003611:0.013987:0.004088:0.003611:0.008902:0.005603:0.010314:0.010355:0.005043:0.008218:0.006973:0.003611:0.009857:0.010687:0.003611:0.006018:0.010272:0.008218:0.003611:0.010065:0.006765:0.009836:0.010334:0.008363:0.008965:0.008010:0.005852:0.005043:0.009857:0.010687:0.003735
in vitro:@0.677432:0.901709:0.730191:0.901709:0.730191:0.882997:0.677432:0.882997:0.004628:0.010272:0.003683:0.008446:0.004729:0.005333:0.006641:0.009027
 of poliomyelitis :@0.730191:0.901709:0.856693:0.901709:0.856693:0.883188:0.730191:0.883188:0.003611:0.009857:0.005644:0.003611:0.010459:0.009940:0.004773:0.005043:0.009857:0.015688:0.008653:0.008135:0.004773:0.004794:0.005852:0.005105:0.006973:0.003735